MXD4 Antibody

What is MXD4 and why is it important in molecular biology research?

MXD4 (MAX Dimerization Protein 4), also known as MAD4, functions as a transcriptional repressor that plays a crucial role in regulating gene expression involved in cell cycle control and development. MXD4 binds with MAX to form a sequence-specific DNA-binding protein complex that recognizes the core sequence 5'-CAC[GA]TG-3'. By competing with MYC for MAX binding, MXD4 antagonizes MYC transcriptional activity and suppresses MYC-dependent cell transformation . The involvement of MXD4 in these processes makes it an important target for research on diseases related to abnormal cell growth and differentiation, particularly cancer .

What applications are MXD4 antibodies commonly used for?

MXD4 antibodies are primarily used in the following applications:

The choice of application depends on your experimental goals. Western blotting is ideal for quantifying protein expression levels, ELISA for protein detection in solution, and IHC for visualizing cellular localization .

What is the difference between polyclonal and monoclonal MXD4 antibodies?

The search results show that most commercially available MXD4 antibodies are polyclonal, generated in rabbits or goats. Polyclonal antibodies recognize multiple epitopes on the MXD4 protein, which can provide stronger signals but potentially less specificity compared to monoclonal antibodies .

How should MXD4 antibodies be stored and handled for optimal results?

For optimal performance of MXD4 antibodies:

• Store at -20°C for long-term storage

• Aliquot to avoid repeated freeze-thaw cycles

• For short-term use (up to 6 months), refrigeration at 2-8°C is acceptable

• Storage buffers typically contain PBS with 0.02% sodium azide and 50% glycerol at pH 7.3

• Handle sodium azide-containing products with appropriate safety precautions

Proper storage and handling is crucial for maintaining antibody activity and ensuring reproducible experimental results over time.

How do I choose the appropriate MXD4 antibody for my specific experimental needs?

Selection criteria should include:

• Target region specificity: Determine whether N-terminal or C-terminal targeting is more appropriate for your research question. For example, if studying protein interactions involving the C-terminal domain, an antibody targeting the N-terminus might be preferable to avoid interference .

• Host species compatibility: Consider your experimental design to avoid cross-reactivity. If performing co-immunoprecipitation with antibodies from other species, choose an MXD4 antibody from a different host .

• Reactivity: Verify species reactivity with your experimental system. Different antibodies show reactivity with human, mouse, rat, or other species .

• Validation data: Review validation evidence for your specific application. The most reliable antibodies will have validation in multiple applications with clear documentation of specificity tests .

• Immunogen sequence: Check that the epitope is accessible in your experimental conditions and not affected by post-translational modifications or protein interactions .

What controls should I include when using MXD4 antibodies in Western blot experiments?

A robust Western blot experiment with MXD4 antibodies should include:

• Positive control: Mouse lung tissue lysate has been validated as a positive control for MXD4 detection .

• Negative control: Include samples known to express very low levels of MXD4 or use siRNA knockdown samples.

• Peptide competition: To confirm specificity, pre-incubate the antibody with the immunizing peptide - this should block the appearance of the specific band (~22-30 kDa) .

• Loading control: Use antibodies against housekeeping proteins (e.g., actin, GAPDH) to normalize protein loading .

• Molecular weight markers: MXD4 has a calculated MW of 24 kDa but is often observed at approximately 30 kDa on Western blots .

How can I optimize immunohistochemistry protocols for MXD4 detection in tissue samples?

Optimization strategies for IHC with MXD4 antibodies:

• Antigen retrieval: Heat-induced epitope retrieval in citrate buffer (pH 6.0) is generally effective for MXD4 detection in paraffin-embedded tissues.

• Antibody dilution: Start with 1:50 dilution as tested in human brain tissue and optimize based on signal-to-noise ratio .

• Incubation conditions: Overnight incubation at 4°C often yields better results than shorter incubations at room temperature.

• Detection system: Use a detection system compatible with your primary antibody host species, considering whether amplification steps are needed.

• Validation controls: Always include a peptide competition control where the primary antibody is pre-incubated with the immunizing peptide, which should eliminate specific staining .

How can MXD4 antibodies be used to study the MYC-MAX-MXD network in cancer research?

The MYC-MAX-MXD network is crucial in regulating cell proliferation, and understanding this network is important for cancer research. MXD4 antibodies can be used to:

• Co-immunoprecipitation assays: Use MXD4 antibodies to isolate protein complexes and identify interaction partners, particularly MAX and other network components.

• ChIP assays: Chromatin immunoprecipitation with MXD4 antibodies can identify genomic binding sites and target genes, particularly those with the core sequence 5'-CAC[GA]TG-3' .

• Dual immunofluorescence: Co-staining for MXD4 and MYC/MAX can reveal competitive binding dynamics in different cell types or under different conditions.

• Cell cycle analysis: Correlate MXD4 expression with cell cycle phases to understand its role in proliferation regulation.

• Transcriptional reporter assays: Measure the impact of MXD4 on target gene expression using reporter constructs containing MXD4 binding sites .

What is known about MXD4's role in leukemia, and how can antibodies help investigate this function?

Recent research has identified MXD4 as a key player in leukemogenesis:

• Expression profiling: MXD4 expression is significantly lower in relapsed acute myeloid leukemia (AML) patients, and low expression is associated with higher relapse rates .

• Epigenetic regulation: UHRF1 directly binds to the MXD4 promoter and represses its expression through DNA methylation. Knockdown of UHRF1 decreases MXD4 DNA methylation and increases its expression .

• Functional studies: MXD4 knockdown can rescue the defects in leukemia initiating cells (LICs) caused by UHRF1 deficiency, suggesting MXD4 plays a tumor-suppressive role .

MXD4 antibodies can be applied in these research contexts for:

• Monitoring MXD4 protein levels in patient samples using IHC or Western blotting

• ChIP-seq studies to identify MXD4 target genes in leukemic cells

• Analyzing correlations between MXD4 expression and clinical outcomes

• Investigating protein-protein interactions within the UHRF1-SAP30-MXD4 axis

How do I troubleshoot non-specific binding or background issues with MXD4 antibodies?

When encountering high background or non-specific binding:

• Antibody dilution optimization: Test a range of dilutions to find the optimal concentration that balances specific signal with minimal background.

• Blocking optimization: Increase blocking time or try alternative blocking agents (BSA, normal serum, commercial blockers) that match your experimental system.

• Washing stringency: Increase wash buffer stringency by adding more detergent (0.1-0.3% Tween-20) or salt (up to 500 mM NaCl).

• Pre-adsorption: Pre-incubate the antibody with tissues or cell lysates from species with high homology but not expressing your target.

• Secondary antibody controls: Run controls with secondary antibody only to identify potential direct binding to your samples.

• Fixation effects: For IHC/ICC, test different fixation methods as overfixation can cause high background while underfixation may cause poor signal .

What approaches can be used to study MXD4 post-translational modifications using antibodies?

Studying MXD4 post-translational modifications (PTMs) requires specialized approaches:

• Phosphorylation-specific antibodies: Though not mentioned in the search results, phospho-specific MXD4 antibodies could be developed to study regulatory phosphorylation events.

• 2D gel electrophoresis: Combine with Western blotting using MXD4 antibodies to separate protein isoforms based on charge differences from PTMs.

• IP-MS workflow: Immunoprecipitate MXD4 using validated antibodies, followed by mass spectrometry to identify PTMs.

• Phosphatase treatment: Compare Western blot patterns before and after phosphatase treatment to identify shifts due to phosphorylation.

• PTM interplay analysis: Study how different modifications (phosphorylation, ubiquitination, acetylation) affect MXD4 function using combinations of inhibitors and activators of PTM enzymes before detection with MXD4 antibodies.

How can MXD4 antibodies be used to evaluate potential therapeutic strategies targeting the MYC pathway?

MXD4 antibodies can support therapeutic development by:

• Target engagement studies: Measure how potential MYC pathway inhibitors affect MXD4-MAX complex formation using co-immunoprecipitation with MXD4 antibodies.

• Pharmacodynamic biomarkers: Monitor MXD4 expression and localization changes in response to therapy using IHC and Western blotting.

• Resistance mechanisms: Investigate whether altered MXD4 expression correlates with resistance to MYC-targeting therapies.

• Combination therapy assessment: Evaluate how combining MYC inhibitors with epigenetic regulators affects MXD4 expression and function, given the connection between UHRF1 and MXD4 regulation .

• Patient stratification strategies: Develop IHC protocols using MXD4 antibodies to identify patient subgroups that might benefit from specific targeted therapies based on MXD4 expression patterns .

What is the relationship between MXD4 and DNA methylation, and how can this be studied using antibodies?

The search results reveal an important relationship between MXD4 and DNA methylation:

• Epigenetic regulation: UHRF1 regulates MXD4 expression through DNA methylation at its promoter. Knockdown of UHRF1 decreases MXD4 DNA methylation and increases its expression .

• Methodological approach: This relationship can be studied using:

  • ChIP assays with UHRF1 and MXD4 antibodies to analyze protein binding to the MXD4 promoter

  • Bisulfite sequencing to assess DNA methylation levels at the MXD4 promoter

  • Western blotting with MXD4 antibodies to measure protein expression changes following treatment with DNA methylation inhibitors

  • Combined ChIP-bisulfite sequencing to correlate protein binding with methylation status

• Functional significance: The UHRF1-SAP30-MXD4 axis appears to be essential for leukemogenesis, with MXD4 repression contributing to leukemia progression .

How do different MXD4 antibodies perform in detecting endogenous versus overexpressed protein?

This is an important consideration for experimental design:

• Sensitivity differences: Some antibodies may preferentially detect high levels of overexpressed protein while struggling with endogenous detection. The search results indicate that most validated MXD4 antibodies can detect endogenous protein in tissues like mouse lung .

• Epitope accessibility: In overexpression systems, epitope accessibility may differ from endogenous conditions due to altered protein folding or interactions.

• Validation approach:

  • Test antibody performance in both wild-type samples and those with MXD4 knockdown/knockout

  • Compare detection in tissues known to have high versus low expression

  • Validate with multiple antibodies targeting different epitopes

  • Use blocking peptides to confirm specificity in both contexts

• Application-specific optimization: Dilution ratios may need adjustment between detecting overexpressed versus endogenous protein (typically requiring more concentrated antibody for endogenous detection).

What are the best practices for using MXD4 antibodies in ChIP and ChIP-seq experiments?

For chromatin immunoprecipitation applications:

• Antibody selection: Choose MXD4 antibodies specifically validated for ChIP applications. The search results don't explicitly mention ChIP validation for commercial MXD4 antibodies, but research-grade antibodies from specialized labs might be available .

• Crosslinking conditions: Test different formaldehyde concentrations (0.75-2%) and incubation times to optimize crosslinking efficiency.

• Chromatin fragmentation: Optimize sonication conditions to achieve 200-500 bp fragments for high-resolution ChIP-seq.

• Control antibodies: Include IgG controls from the same species as your MXD4 antibody, and consider including antibodies against known MXD4 binding partners as positive controls.

• Enrichment validation: Perform qPCR on known MXD4 target regions before proceeding to sequencing to confirm successful enrichment.

• Data analysis: When analyzing MXD4 ChIP-seq data, focus on motifs containing the core sequence 5'-CAC[GA]TG-3', which is recognized by the MXD4-MAX complex .

How can MXD4 antibodies be effectively used in multiplexed immunofluorescence with other transcription factor antibodies?

Multiplexed detection requires careful planning:

• Antibody compatibility: Select MXD4 antibodies from different host species than other target antibodies to avoid cross-reactivity of secondary antibodies.

• Signal separation: If using fluorescent detection, ensure fluorophores have minimal spectral overlap and include appropriate controls for bleed-through.

• Sequential staining: For challenging combinations, consider sequential staining with complete antibody stripping between rounds.

• Validation controls: Include single-stain controls to validate each antibody separately before multiplexing.

• Nuclear factors optimization: Since MXD4 is a nuclear protein, optimize nuclear permeabilization conditions to ensure access to all nuclear transcription factors while maintaining morphology.

• Cross-blocking: If using multiple rabbit antibodies, consider directly conjugated primary antibodies or use specialized multiplexing systems like Tyramide Signal Amplification .

What are the considerations when using MXD4 antibodies in proximity ligation assays to study protein-protein interactions?

Proximity Ligation Assay (PLA) for studying MXD4 interactions:

• Antibody validation: Confirm that the MXD4 antibody epitope is not involved in the protein interaction you're studying, as antibody binding could interfere with the interaction.

• Paired antibody selection: Choose antibodies raised in different species for your protein pair (e.g., rabbit anti-MXD4 with mouse anti-MAX).

• Antibody concentration: PLA typically requires lower antibody concentrations than standard immunofluorescence, so optimize dilutions specifically for PLA.

• Fixation optimization: Test different fixation protocols as they can significantly affect epitope accessibility and detection of transient interactions.

• Negative controls: Include controls where one primary antibody is omitted and single-transfected cells expressing only one of the interaction partners.

• Positive controls: Include known interaction partners of MXD4, such as MAX, as positive controls to validate your assay conditions .